Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

[1]  M. Casey,et al.  Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data , 2007 .

[2]  R. Tuma.  Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. , 2007, Journal of the National Cancer Institute.

[3]  R. Nahta,et al.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling , 2007, Molecular Cancer Therapeutics.

[4]  S. Stein,et al.  Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. , 2007, Cancer research.

[5]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[6]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[7]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[8]  G. Carpenter,et al.  ErbB receptors: new insights on mechanisms and biology. , 2006, Trends in cell biology.

[9]  K. Hess,et al.  Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Lotan,et al.  Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways , 2006, Breast Cancer Research.

[11]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Eisenhauer,et al.  Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[14]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[15]  C. Swanton,et al.  Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab , 2006, Acta oncologica.

[16]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[17]  N. Spector,et al.  Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells , 2005, Oncogene.

[18]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Rowinsky,et al.  A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients , 2005 .

[20]  Suzanne F. Jones,et al.  A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen , 2005 .

[21]  M. Berger,et al.  Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer , 2005 .

[22]  Simak Ali,et al.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. , 2005, The Lancet. Oncology.

[23]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Blackwell,et al.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. , 2005, Cancer research.

[26]  M. Cristofanilli,et al.  Systemic treatments for inflammatory breast cancer. , 2005, Breast disease.

[27]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Bisegna,et al.  Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[30]  M. Mita,et al.  Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. , 2004, Journal of Clinical Oncology.

[31]  David A. Smith,et al.  Clinical activity of GW572016 in EGF10003 in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Spector,et al.  Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 , 2004, Oncogene.

[33]  A. Stead,et al.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects , 2004, Investigational New Drugs.

[34]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[35]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  K. Lackey,et al.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[37]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[38]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[39]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Williams.  Inflammatory breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.